Hallgeir Rui, MD, PhD
233 South Tenth Street,
Philadelphia, PA 19107
(215) 503-9246 fax
Most Recent Peer-reviewed Publications
- Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression
- Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth
- Triggering ubiquitination of IFNAR1 protects tissues from inflammatory injury
- NADPH oxidase subunit p22phox-mediated reactive oxygen species contribute to angiogenesis and tumor growth through AKT and ERK1/2 signaling pathways in prostate cancer
- Prolactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment
MD, University of Oslo, Norway - 1980-1987
PhD, Pathology, University of Oslo, Norway - 1983-1988
Expertise & Research Interests
Dr. Rui has made a series of contributions to increased understanding of the molecular mechanisms of signal transduction by cytokine receptors and hormones. Dr. Rui was the first to isolate a prolactin receptor-associated tyrosine kinase, and to identify this molecule as Janus kinase-2. Dr. Rui's laboratory has maintained a focus on cytokine and hormone receptor function with a primary goal of understanding the role of downstream Jak-Stat pathways and their aberrations in breast cancer.
Activation of Stat5 is a strong favorable prognostic marker in breast cancer and an invasion-suppressive role of Stat5 in human breast cancer may represent a biological mechanism. Loss of Stat5 in estrogen-receptor-positive breast cancer is associated with increased risk of antiestrogen resistance. Dr. Rui and his team have invented and patented cutting-edge matrix assembly technology for generation of high density tumor tissue arrays for high-through-put molecular profiling. Dr. Rui is the PI of a $6.7 million, 5 year Komen Promise Grant to a consortium of multidisciplinary investigators to classify malignant breast tumors based on quantitative expression of druggable target proteins for improved personalized cancer care. Advanced quantitative immunofluorescence-based histocytometry technologies are being used. This consortium project also involves a novel Bayesian adaptive biomarker-centered Phase II clinical trial of a Parp-inhibitor in the neoadjuvant setting for triple-negative breast cancer.
cancer; breast cancer; cytokine receptors, hormone; endocrinology; prolactin; growth hormone; estrogen; glucocorticoid; steroid hormones; Jak2; Stat5; Stat5a; Stat5b; immunohistochemistry; pathology; biomarker; early detection; microarray; tissue microarray; mouse modeling; EGFR; Her2; ErbB2; prolactin receptor